Showing 6,661 - 6,680 results of 27,428 for search '(( a teer decrease ) OR ( 50 ((((we decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 0.80s Refine Results
  1. 6661
  2. 6662
  3. 6663
  4. 6664

    PCAIs inhibit NCI-H23 cell line viability. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  5. 6665

    PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  6. 6666

    PCAIs suppress 3D NCI-H23 cell invasion. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  7. 6667

    PCAIs suppress NCI-H23 cancer cell migration. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  8. 6668

    PCAIs induce apoptosis in NCI-H23 cells. by Matthew D. Gregory (19929096)

    Published 2024
    “…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”
  9. 6669
  10. 6670
  11. 6671
  12. 6672

    DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells by Chong Guo (5819105)

    Published 2025
    “…Knocking down of DNMT1 could decrease the IC<sub>50</sub> of cisplatin. Treatment with cisplatin may reduce FOXO3a expression in OC cells. …”
  13. 6673
  14. 6674
  15. 6675

    Suppression by extracellular QRNA from TNP Ts Sup free of exosomes, or miR-150 alone, associating with B-cell derived Ag-specific exosomes from the assayed CS-effector cell mixture... by Krzysztof Bryniarski (731989)

    Published 2015
    “…</b></u> Similarly, two day immune B-1 B cell-derived exosomes, supplemented with decreasing doses of miR-150 alone, mediated suppression of TNP-CS-effector cell adoptive transfer (Groups E-G), down to a dose of 750pg per eventual recipient, which is 50 femtomoles per eventual recipient (Group G). …”
  16. 6676

    Drebrin regulates RMS neuroblast migration <i>in vitro</i>. by Martina Sonego (481270)

    Published 2015
    “…The GFP channel is shown as a grayscale image. (B) Drebrin-depleted neuroblasts (black column) show a ~20% decrease in migration distance compared to control shRNA-nucleofected cells (white column). …”
  17. 6677
  18. 6678
  19. 6679
  20. 6680

    Rho inactivation negatively affects biofilm formation in <i>B</i>. <i>subtilis</i>. by Vladimir Bidnenko (4258573)

    Published 2017
    “…(B and C) Rho inactivation decreases expression of biofilm-specific genes. Promoters of the operons <i>epsA-O</i> (B) and <i>tapA-sipW-tasA</i> (C) encoding exopolysaccharides and amyloid-like protein fibers, respectively, were fused to the butterfly luciferase gene <i>luc</i> and tested for transcription activity in <i>B</i>. …”